Skip to content

Abstract 13527: Real World Evidence of the Consequences of Bleeding Events on Anticoagulant Use in Patients with Atrial Fibrillation in the United States

Nov 2026 · Circulation · 0 citations

Abstract

Background: Oral anticoagulation (OAC) reduces stroke risk in atrial fibrillation (AF), but major bleeding (MB) remains a concern. Current evidence on post-bleeding treatment patterns is limited. Question: How does bleeding influence OAC treatment patterns in the real-world? Methods: This retrospective study used Optum Clinformatics data (2016-2023). Index date was first AF diagnosis and follow-up ended at death, disenrollment, or study end. Assessed metrics included the proportion of days covered (PDC), OAC interruptions defined as ≥30-day gaps per 100 person-years (PY), and permanent OAC discontinuation defined as ≥90-day treatment gap without OAC through end of follow-up. Within-patient analysis, which inherently adjusts for patient-level confounders, compared pre- versus post-MB periods (minimum 90 days follow-up in each period) overall and by first MB type. Results: We identified 232,156 AF patients initiating OAC; of these, 33,424 (14.4%) experienced MB after OAC initiation. Mean follow-up was 1,373 days (all patients) and 1,412 days (patients with MB). Patients with MB were older (75.4 vs 73.2 years) with higher CHA 2 DS 2 -VASc (4.9 vs 4.1) and HAS-BLED (2.6 vs 2.1) scores vs patients without MB. Patients with MB had PDC of 59% and interruption rate of 44.9 per 100 PY; patients without MB had PDC of 64% and interruption rate of 40.0 per 100 PY. Within-patient analysis (n=18,816) showed post-MB PDC decline of 27.4% with interruption rate increasing from 25.1 to 45.1 per 100 PY (1.80-fold increase). Permanent OAC discontinuation occurred in 27.3% post-MB. Patients with intracranial hemorrhage (n=2,354) showed the largest PDC decline of 33.7% with interruption rate increasing from 22.3 to 39.5 per 100 PY (1.77-fold increase). Patients with gastrointestinal bleeding (n=10,638) showed PDC decline of 28.9% with interruption rate increasing from 25.6 to 45.8 per 100 PY (1.79-fold increase). Conclusions: Bleeding disrupts OAC management, potentially reducing adherence, increasing OAC interruptions, and causing permanent therapy cessation, which may leave patients exposed to elevated thromboembolic risk. Further research should assess post-bleeding clinical and economic outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.